Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   17:10
140,17 USD (-1,49%)
(-1,49%)   17:10
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. in het nieuws

14 mei 2024 · Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 · Persbericht

9 mei 2024 · Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 · Persbericht

9 mei 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults · Persbericht

8 mei 2024 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults · Persbericht

7 mei 2024 · Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference · Persbericht

7 mei 2024 · Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 · Persbericht

6 mei 2024 · Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring · Persbericht

3 mei 2024 · Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 · Persbericht

1 mei 2024 · Neurocrine Biosciences Reports First Quarter 2024 Financial Results · Persbericht

30 april 2024 · Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Kevin Gorman

Werknemers: 1.252

Aandelen Neurocrine Biosciences, Inc.

Beurswaarde: 14,32 miljard USD

Effecten: 100,64 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,36

Mijn selecties